Shanghai innovative bio-medicine service provider dMed raised nearly $50 Million in a series B round funding led by Vivo Capital, and followed by Legend Capital, Qiming Venture Partners, and Lilly Asia Ventures. The investment will be used to improve the capacity of clinical operation and digitalization and accelerate the strategic launch in overseas market.
Established in 2016, dMed is a global CRO. It provides premium, all round clinical service to Chinese and global bio-medicine companies and medical equipment companies. Its service include solution design, application strategies, operation, and quality assurance.
South Africa Today